Natco Pharma ends 5% higher as US Supreme Court invalidates rival Teva's patent for Copaxone

MUMBAI: The United States Supreme Court has found Teva Pharmaceuticals' patent for drug Copaxone as invalid, Natco Pharma today said.

Copaxone (Glatiramer Acetate) is used in the treatment of relapsing-remitting multiple sclerosis.

Shares of Natco Pharma surged as much as 7.87 per cent in intraday trade on Friday. The stock ended the day in green, up 5.58 per cent or Rs 115.85 at Rs 2,192.3.

In a filing to BSE, Natco said the US Court of Appeals for Federal Circuit has again found Teva's US "patent no. 5.800.808' (the 808 patent)" for Copaxone to be invalid.

The company awaits USFDA approval to launch the product, it said.

According to reports, Copaxone accounted for USD 3.1 billion out of Teva's total revenue of USD 15.1 billion in the first nine months of the past year.